81 related articles for article (PubMed ID: 18835771)
1. Impact of MDM2 SNP309 genotype on progression and survival of stage 4 neuroblastoma.
Perfumo C; Parodi S; Mazzocco K; Defferrari R; Inga A; Haupt R; Fronza G; Tonini GP
Eur J Cancer; 2008 Nov; 44(17):2634-9. PubMed ID: 18835771
[TBL] [Abstract][Full Text] [Related]
2. MDM2 SNP309 genotype influences survival of metastatic but not of localized neuroblastoma.
Perfumo C; Parodi S; Mazzocco K; Defferrari R; Inga A; Scarrà GB; Ghiorzo P; Haupt R; Tonini GP; Fronza G
Pediatr Blood Cancer; 2009 Oct; 53(4):576-83. PubMed ID: 19526525
[TBL] [Abstract][Full Text] [Related]
3. MDM2 SNP309 genotype is associated with ferritin and LDH serum levels in children with stage 4 neuroblastoma.
Parodi S; Perfumo C; Garaventa A; Inga A; Mazzocco K; Defferrari R; Tonini GP; Fronza G; Haupt R
Pediatr Blood Cancer; 2010 Aug; 55(2):267-72. PubMed ID: 20232446
[TBL] [Abstract][Full Text] [Related]
4. Lack of association between MDM2 promoter SNP309 and clinical outcome in patients with neuroblastoma.
Rihani A; Van Maerken T; De Wilde B; Zeka F; Laureys G; Norga K; Tonini GP; Coco S; Versteeg R; Noguera R; Schulte JH; Eggert A; Stallings RL; Speleman F; Vandesompele J
Pediatr Blood Cancer; 2014 Oct; 61(10):1867-70. PubMed ID: 24391119
[TBL] [Abstract][Full Text] [Related]
5. Impact of a single nucleotide polymorphism in the MDM2 gene on neuroblastoma development and aggressiveness: results of a pilot study on 239 patients.
Cattelani S; Defferrari R; Marsilio S; Bussolari R; Candini O; Corradini F; Ferrari-Amorotti G; Guerzoni C; Pecorari L; Menin C; Bertorelle R; Altavista P; McDowell HP; Boldrini R; Dominici C; Tonini GP; Raschellà G; Calabretta B
Clin Cancer Res; 2008 Jun; 14(11):3248-53. PubMed ID: 18519749
[TBL] [Abstract][Full Text] [Related]
6. Associations of MDM2 SNP309, transcriptional activity, mRNA expression, and survival in stage I non-small-cell lung cancer patients with wild-type p53 tumors.
Chien WP; Wong RH; Cheng YW; Chen CY; Lee H
Ann Surg Oncol; 2010 Apr; 17(4):1194-202. PubMed ID: 19941079
[TBL] [Abstract][Full Text] [Related]
7. MDM2 promoter SNP309 is associated with an increased susceptibility to chronic lymphocytic leukemia and correlates with MDM2 mRNA expression in Chinese patients with CLL.
Dong HJ; Fang C; Fan L; Zhu DX; Wang DM; Zhu HY; Zhuang Y; Miao KR; Liu P; Xu W; Li JY
Int J Cancer; 2012 May; 130(9):2054-61. PubMed ID: 21647873
[TBL] [Abstract][Full Text] [Related]
8. MDM2 SNP309 polymorphism as risk factor for susceptibility and poor prognosis in renal cell carcinoma.
Hirata H; Hinoda Y; Kikuno N; Kawamoto K; Suehiro Y; Tanaka Y; Dahiya R
Clin Cancer Res; 2007 Jul; 13(14):4123-9. PubMed ID: 17634539
[TBL] [Abstract][Full Text] [Related]
9. MDM2 SNP309 is associated with poor outcome in B-cell chronic lymphocytic leukemia.
Gryshchenko I; Hofbauer S; Stoecher M; Daniel PT; Steurer M; Gaiger A; Eigenberger K; Greil R; Tinhofer I
J Clin Oncol; 2008 May; 26(14):2252-7. PubMed ID: 18467716
[TBL] [Abstract][Full Text] [Related]
10. MDM2 SNP309 modifies the prognostic significance of the p53 mutational status in patients with ovarian cancer.
Hofstetter G; Berger A; Bauer EM; Schuster E; Wolf A; Chamson M; Müller-Holzner E; Reimer D; Braicu EI; Sehouli J; Ulmer H; Cacsire Castillo-Tong D; Zeillinger R; Concin N
Oncol Rep; 2012 Mar; 27(3):673-7. PubMed ID: 22134502
[TBL] [Abstract][Full Text] [Related]
11. Association of p53 codon 72 polymorphism and MDM2 SNP309 with clinical outcome of advanced nonsmall cell lung cancer.
Han JY; Lee GK; Jang DH; Lee SY; Lee JS
Cancer; 2008 Aug; 113(4):799-807. PubMed ID: 18618574
[TBL] [Abstract][Full Text] [Related]
12. Association of breast cancer outcome with status of p53 and MDM2 SNP309.
Boersma BJ; Howe TM; Goodman JE; Yfantis HG; Lee DH; Chanock SJ; Ambs S
J Natl Cancer Inst; 2006 Jul; 98(13):911-9. PubMed ID: 16818855
[TBL] [Abstract][Full Text] [Related]
13. Influence of MDM2 SNP309 alone or in combination with the TP53 R72P polymorphism in oligodendroglial tumors.
Idbaih A; Boisselier B; Marie Y; Sanson M; El Hallani S; Crinière E; Fourtassi M; Paris S; Carpentier C; Rousseau A; Mokhtari K; Combadière C; Laigle-Donadey F; Hoang-Xuan K; Delattre JY
Brain Res; 2008 Mar; 1198():16-20. PubMed ID: 18262501
[TBL] [Abstract][Full Text] [Related]
14. MDM2 SNP309 does not confer an increased risk to oral squamous cell carcinoma but may modulate the age of disease onset.
Hamid S; Yang YH; Peng KN; Ismail SM; Zain RB; Lim KP; Wan Mustafa WM; Abraham MT; Teo SH; Cheong SC
Oral Oncol; 2009 Jun; 45(6):496-500. PubMed ID: 18804411
[TBL] [Abstract][Full Text] [Related]
15. Effect of TP53 Arg72Pro and MDM2 SNP309 polymorphisms on the risk of high-grade osteosarcoma development and survival.
Toffoli G; Biason P; Russo A; De Mattia E; Cecchin E; Hattinger CM; Pasello M; Alberghini M; Ferrari C; Scotlandi K; Picci P; Serra M
Clin Cancer Res; 2009 May; 15(10):3550-6. PubMed ID: 19451596
[TBL] [Abstract][Full Text] [Related]
16. Effect of MDM2 SNP309 and p53 codon 72 polymorphisms on lung cancer risk and survival among non-smoking Chinese women in Singapore.
Chua HW; Ng D; Choo S; Lum SS; Li H; Soh LY; Sabapathy K; Seow A
BMC Cancer; 2010 Mar; 10():88. PubMed ID: 20219101
[TBL] [Abstract][Full Text] [Related]
17. Lack of association between the MDM2 promoter polymorphism SNP309 and clinical outcome in chronic lymphocytic leukemia.
Kaderi MA; Mansouri M; Zainuddin N; Cahill N; Gunnarsson R; Jansson M; Kimby E; Aleskog A; Lundin J; Glimelius B; Melbye M; Juliusson G; Jurlander J; Rosenquist R
Leuk Res; 2010 Mar; 34(3):335-9. PubMed ID: 19573916
[TBL] [Abstract][Full Text] [Related]
18. Risk of MDM2 SNP309 alone or in combination with the p53 codon 72 polymorphism in acute myeloid leukemia.
Xiong X; Wang M; Wang L; Liu J; Zhao X; Tian Z; Wang J
Leuk Res; 2009 Nov; 33(11):1454-8. PubMed ID: 19423162
[TBL] [Abstract][Full Text] [Related]
19. A functional SNP in the MDM2 promoter, pigmentary phenotypes, and risk of skin cancer.
Nan H; Qureshi AA; Hunter DJ; Han J
Cancer Causes Control; 2009 Mar; 20(2):171-9. PubMed ID: 18814047
[TBL] [Abstract][Full Text] [Related]
20. The MDM2 promoter polymorphism SNP309T-->G and the risk of uterine leiomyosarcoma, colorectal cancer, and squamous cell carcinoma of the head and neck.
Alhopuro P; Ylisaukko-Oja SK; Koskinen WJ; Bono P; Arola J; Järvinen HJ; Mecklin JP; Atula T; Kontio R; Mäkitie AA; Suominen S; Leivo I; Vahteristo P; Aaltonen LM; Aaltonen LA
J Med Genet; 2005 Sep; 42(9):694-8. PubMed ID: 16141004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
